JYNT
The Joint Corp.
NASDAQ · Healthcare · Medical - Care Facilities · US
$8.32
+0.48%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 58.5M | 54.9M | 52.2M | 47.0M | 101.3M |
| Cost of Revenue | 11.1M | 11.2M | 11.5M | 10.5M | 9.2M |
| Gross Profit | 47.5M | 43.7M | 40.6M | 36.5M | 92.1M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 44.3M | 42.9M | 41.1M | 34.9M | 82.0M |
| General & Admin Expense | 29.4M | 29.6M | 30.1M | 26.2M | 68.0M |
| Selling & Marketing Expense | 14.9M | 13.3M | 11.0M | 8.7M | 14.0M |
| Other Expenses | 1.7M | 1.6M | 1.4M | 1.3M | 9.3M |
| Total Operating Expenses | 46.0M | 44.6M | 42.5M | 36.2M | 91.3M |
| Cost and Expenses | 57.1M | 55.8M | 54.1M | 46.7M | 100.4M |
| Operating Income (EBIT) | 1.4M | (905.5K) | (1.9M) | 318.3K | 828.3K |
| Non-Operating | |||||
| Interest Income | 126.4K | — | 280.3K | — | 133.1K |
| Interest Expense | — | — | — | 64.3K | 953.5K |
| Net Interest Income | 126.4K | — | 280.3K | (64.3K) | (820.4K) |
| Other Non-Op Income/Expense | 677.9K | 676.0K | 280.3K | (64.3K) | (133.1K) |
| Non-Operating Income (excl Interest) | (677.9K) | (676.0K) | (66.0K) | 20.9K | (410.2K) |
| EBT (Pre-Tax Income) | 2.1M | (229.5K) | (1.6M) | 254.0K | 695.2K |
| Income Tax Expense | 34.1K | 38.7K | 5.6K | 11.0M | 68.4K |
| Bottom Line | |||||
| Net Income | 3.8M | 2.9M | (5.8M) | (9.8M) | 626.7K |
| Earnings from Cont. Ops | 2.1M | (268.2K) | (1.6M) | (10.8M) | 626.7K |
| Earnings from Discont. Ops | 1.7M | 3.2M | (4.2M) | 1.0M | — |
| Bottom Line Net Income | 3.8M | 2.9M | (5.8M) | (9.8M) | 626.7K |
| Per Share | |||||
| Basic EPS | $0.27 | $0.19 | ($0.39) | ($0.66) | $0.04 |
| Diluted EPS | $0.27 | $0.19 | ($0.39) | ($0.66) | $0.04 |
| Revenue Per Share | $4.11 | $3.63 | $3.50 | $3.20 | $6.99 |
| Shares | |||||
| Basic Shares Outstanding | 14.2M | 15.1M | 14.9M | 14.7M | 14.5M |
| Diluted Shares Outstanding | 14.2M | 15.1M | 15.1M | 14.7M | 14.9M |
| Profitability Metrics | |||||
| EBITDA | 3.8M | 1.5M | 2.9M | 8.9M | 7.9M |
| D&A | 1.7M | 1.7M | 4.7M | 8.6M | 6.6M |
| EBIT | 2.1M | (229.5K) | (1.8M) | 297.4K | 1.2M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026